Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5593563 | 0.99 | HTT (0.47) | HTTSMN1; SMN2GAAATMHSD17B10 | |
| SCHEMBL10493808 | 0.88 | HSD17B10 (0.50) | HTTSMN1; SMN2GAAATMHSD17B10 | |
| SCHEMBL10493810 | 0.87 | HSD17B10 (0.49) | HTTSMN1; SMN2GAAATMHSD17B10 | |
| SCHEMBL9770175 | 0.87 | HSD17B10 (0.49) | HTTSMN1; SMN2GAAATMHSD17B10 | |
| SCHEMBL5232567 | 0.80 | MAPT (0.44) | HTTSMN1; SMN2GAAL3MBTL1ALDH1A1 | |
| SCHEMBL9770335 | 0.76 | HSD17B10 (0.56) | HTTSMN1; SMN2HSD17B10L3MBTL1ALDH1A1 | |
| SCHEMBL5197330 | 0.75 | MEN1 (0.55) | HTTSMN1; SMN2GAAHSD17B10L3MBTL1 | |
| SCHEMBL8944106 | 0.73 | GAA (0.45) | HTTSMN1; SMN2GAAATMHSD17B10 | |
| SCHEMBL8944199 | 0.73 | GAA (0.45) | HTTSMN1; SMN2GAAATMHSD17B10 | |
| SCHEMBL12769185 | 0.73 | HSD17B10 (0.52) | HTTSMN1; SMN2HSD17B10L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087640-A1 | Method for production of aryl-substituted annelated pyrimidines | BASF SE (DE) | 2010-04-08 | — | — | US | disclosed |
| EP-2111404-A1 | METHOD FOR PRODUCTION OF ARYL-SUBSTITUTED ANNELATED PYRIMIDINES | BASF SE (DE) | 2009-10-28 | — | — | EP | disclosed |
| WO-2008084082-A1 | METHOD FOR PRODUCTION OF ARYL-SUBSTITUTED ANNELATED PYRIMIDINES | BASF SE (DE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087640-A1 | Method for production of aryl-substituted annelated pyrimidines | AOC3, CBR3, AOC2 | HTT 1420/4885SMN1; SMN2 2142/4885GAA 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.